Collectively, the β-Lapachone/oxaliplatin combination leverages a "target inhibition plus DNA damage" strategy, exhibiting potent synergy and strong translational potential, particularly in ARL4C-high, oxaliplatin-resistant CRC. The gene discussed is ARL4C; the disease is colorectal carcinoma.